During acute rejection leukocyte-endothelial cell interaction fuelled by costimulatory molecules such as the CD40/CD154 receptor/ligand dyad disrupts microcirculation of the small bowel. Downregulating endothelial CD40 expression by employing a decoy oligonucleotide (dODN) neutralizing the transcription factor signal transducer and activator of transcription-1 (STAT-1) may protect the graft. Therefore allogenic small bowel transplantation was performed in the Brown Norway to Lewis rat model. Graft vessels were pretreated with STAT-1 dODN, mutant control ODN (20 mM) or vehicle (n ¼ 8). CD40 antisense ODN and scrambled control ODN-treated transplants served as target control (n ¼ 3 each). Intravital microscopy, histology, immunohistochemistry and Western blot analyses were performed 7 days later. Functional capillary density, red blood cell velocity and perfusion index in STAT-1 dODN and CD40 antisense ODN-treated transplants were improved whereas stasis index was reduced. Leukocyteendothelial cell interaction showed no difference. Histological parameters of rejection, infiltrating CD3-positive cells and apoptotic bodies were also reduced in STAT-1 dODN and CD40 antisense ODN-treated transplants 7 days post-transplantation. CD40 protein abundance was reduced to less than 10% of control in STAT-1 dODN-treated grafts. STAT-1 dODN blockade of CD40 expression improves mucosal perfusion, reduces graft rejection, T-cell infiltration and apoptosis in rat small bowel allografts during acute rejection.
Introduction
Small bowel transplantation is still hampered by acute cellular rejection episodes, which constitute a major cause of graft failure and mortality. 1 During such an episode, for example, antigen-presenting cells (APCs) display allogeneic peptides to type 1 T-helper cells (TH1), the activation of which is reinforced through CD40/CD154-dependent costimulation. 2 This costimulation, in case of the endothelial cells of the graft, not only aggravates T-cell activity but boosts the subsequent recruitment of effector leukocytes, namely monocytes. 3 Leukocyte-endothelial cell interaction thus exaggerated, causes damage to the capillary microcirculation, loss of mucosal barrier function, sepsis episodes and ultimately graft loss. 2, 4 Hence, interfering with leukocyteendothelial cell interaction, for example, by chemokine receptor blockade, improves microcapillary perfusion and reduces the histological signs of graft damage. 5 CD40 is a cell-surface receptor belonging to the tumor necrosis factor (TNF) receptor superfamily that is expressed principally by B cells and other APCs, but also by nonimmune cells such as smooth muscle cells, fibroblasts and endothelial cells. 6, 7 The corresponding ligand CD154 is a member of the TNF superfamily and localized primarily on activated T cells, but also on dendritic cells, mast cells, eosinophils, endothelial cells and platelets. 2 Endothelial cell CD40 stimulation results in a profound increase in expression of adhesion molecules and chemokines, which fuels the aforementioned homing and extravasation of leukocytes at the site of inflammation. 8, 9 Moreover, like APCs, endothelial cells produce bioactive IL-12 upon CD40 stimulation, 10 and this may be decisive in strengthening recipient T-cell activity in graft rejection. 11, 12 Ergo, administration of anti-CD154 antibodies prolongs allograft survival in rodent and primate transplantation models. [13] [14] [15] [16] Clinical application of such antibodies, however, resulted in serious thromboembolic complications, 17, 18 presumably owing to the thrombus stabilizing effect of soluble CD154 shed from activated platelets. 19 As low-molecular-weight antagonists for CD40 are not yet available, and antibodies against CD40 stimulate rather than inhibit downstream signalling, 20 we intended to block CD40 expression in the donor endothelial cells by administering a decoy oligodesoxynucleotide (dODN) directed against the transcription factor signal transducer and activator of transcription-1 (STAT-1).
Decoy ODNs are short double-stranded DNA molecules, which are taken up by their respective target cells without the need for a transfection reagent. They mimic the DNA-binding site of the transcription factor, thereby effectively neutralizing it inside the cell and preventing it from stimulating expression of its target genes. 21 Cytokine-stimulated expression of CD40 both in rat and human vascular cells is effectively blocked by a dODN directed against STAT-1. 22, 23 To confirm that the dODN exerts its therapeutic effect in the chosen rat small bowel transplantation model by virtue of this mechanism, its effect was compared to that of a CD40 antisense ODN, which effectively suppresses de novo CD40 protein synthesis in rat vascular cells. 24 As the mucosal microcirculation within the graft villi is the first functional parameter to deteriorate during rejection of the rat small bowel, 5 we analyzed blood flow and functional capillary density (FCD) within the villi by intravital microscopy.
Results

Gross hemodynamics
Mean arterial blood pressure measurements in the carotid artery during intravital microscopy revealed no significant differences between the groups during the experiments (data not shown). Naked double-stranded DNA or liposomal single-stranded DNA application revealed no anaphylactic reaction or influence on mean arterial blood pressure.
Microcirculatory perfusion in the graft mucosa
Seven days post-transplantation, overall villi perfusion in the graft mucosa was significantly improved in STAT-1 dODN-treated transplants as compared to the untreated control or mutant control ODN-treated grafts, respectively. This was shown by the perfusion index, representing the percentage of perfused villi with respect to the observed villi per observation field (Figure 1a) . Conversely, the stasis index, a marker of the percentage of nonperfused villi with respect to the total number of villi per observation field, was significantly reduced in STAT-1 dODN-treated grafts as compared to the untreated control or mutant control ODN-treated transplants, respectively (Figure 1b) .
A more detailed analysis of microcirculatory blood flow by measuring the FCD within a single villus per villus area again showed a significantly higher density of perfused capillaries in STAT-1 dODN-treated allografts compared to the respective control groups (Figure 1c ). This demonstrates a better preserved villus perfusion and hence better mucosal function in STAT-1 dODNtreated allografts.
Accordingly, measuring red blood cell velocity (RBCV) in the villus capillaries revealed a significantly greater velocity in STAT-1 dODN-treated transplants as compared to the untreated control or mutant control ODNtreated grafts, respectively (Figure 1d) .
Leukocyte-endothelial cell interaction
In contrast, evaluation of leukocyte-endothelial cell interaction in submucosal postcapillary venules revealed no significant differences in the number of sticking leukocytes to the endothelial surface between the different treatment and control groups (Figure 1e ). The same was true for CD40 antisense ODN and scrambled control ODN-treated grafts. On the other hand, CD40 antisense ODN treatment appeared to improve microcirculatory perfusion of the graft mucosa to a similar extent as with the STAT-1 dODN (Figures 1a-d) .
Histology/Immunohistochemistry
Histologically graded rejection revealed a significantly lower rejection score in STAT-1 dODN-treated transplants as compared to the untreated control or mutant control ODN-treated grafts, respectively (Figure 2a) . Counting of the CD3-positive cells in the intestinal wall also revealed a significant decrease in T-cell infiltration in STAT-1 dODN-treated transplants as compared to the respective control groups (Figures 2b and 3a-c) . This was also true for the number of apoptotic bodies within the intestinal wall, which served as an index of graft damage (Figures 2c and 3d-f) . Again, CD40 antisense ODN treatment appeared to afford effects very similar to those observed with the STAT-1 dODN (Figures 2a-c) .
Western blot analysis of CD40 protein
Analyzing CD40 protein abundance in the allografts 7-days post-transplantation showed a marked reduction in transplants treated with the STAT-1 dODN as compared to the untreated control or mutant control ODN-treated grafts, respectively ( Figure 4 ). The mutant control ODN also affected CD40 protein levels to some extent, but this effect did not gain statistical significance. Despite the brief periprocedural exposure, these findings demonstrate that treatment with the STAT-1 dODN exerts a long-lasting inhibitory effect on CD40 expression in the transplant vasculature.
Discussion
Despite advances in graft and patient survival following small bowel transplantation, acute rejection episodes still jeopardize long-term outcome.
1 Activated T cells play a major role in allograft rejection. Their activation requires two signals, the first is mediated via the T-cell receptor through the antigen itself and the second, a costimulatory signal, is delivered by APCs, for example, through the CD40/CD154 receptor/ligand dyad. 25 CD40/CD154-mediated costimulation results in upregulation of various cytokines such as interleukins-1, 6, 8, 10 and 12, TNF-a and MIP-1a in dendritic cells as well as an increased expression of adhesion molecules such as E-selectin, ICAM-1 and VCAM-1 in endothelial cells followed by an enhanced infiltration and activation of mononuclear cells in the graft vasculature, ultimately resulting in graft loss. [8] [9] [10] 26 In our study, we attempted to interfere with CD40/ CD154-mediated costimulation at an early step by targeting CD40 expression in the graft endothelium at the level of transcription. For this purpose, we employed a dODN directed against the transcription factor STAT-1. We have shown previously that CD40 expression in rat vascular STAT-1 decoy oligonucleotide and transplant rejection T Stojanovic et al abundance in small bowel allografts following a brief periprocedural exposure of the graft vasculature to the dODN. As this route of administration in combination with an almost quantitative wash out of excess nucleic acid before restoration of blood flow to the organ results in a virtually exclusive uptake of the dODN by the endothelial cells of the graft, 27 this decrease in CD40 protein content most likely has occurred in these cells.
In our hands, single application of the STAT-1 dODN led to an improvement in all microcirculatory and histology/immunohistochemistry parameters measured by a factor of 2 or more when compared to the corresponding mutant control ODN, which did not exert a significant effect on any of these parameters on its own. The only parameter that was not affected by the STAT-1 dODN treatment, and likewise by CD40 antisense ODN treatment, was leukocyte-endothelial cell interaction determined by intravital microscopy. Leukocytes visualized by this technique are stained in vivo with Rhodamine 6G, which is incorporated nonspecifically by all circulating leukocytes, namely neutrophils, and to a lesser degree by endothelial cells. As a consequence, it cannot reveal endothelial cell interaction with the relatively small fraction of CD3-positive T-cells, which were detected in the graft by immunohistochemistry. However, one may speculate that downregulation of CD40 expression in the graft endothelium has resulted in reduced costimulation of the infiltrating T cells and, as a consequence, less damage to the graft.
We have shown previously in the same transplantation model that damage to the mucosal microcirculation is maximal at 7 days post-transplantation with almost complete breakdown of villus perfusion and histologically manifest graft necrosis 3 days later. 5 Treatment with the STAT-1 dODN thus appears to have effectively slowed down acute graft rejection. The clear trend, although statistically not as robust owing to the smaller sample size, of CD40 antisense ODN treatment towards a similar protective effect corroborates our assumption that IFN-g-stimulated transcription of the CD40 gene in the graft endothelial cells is one primary target of the STAT-1 dODN. Preliminary findings with the liposomal antisense ODN formulation, pointing towards a preferential uptake by the graft endothelial cells as well, further validate our hypothesis of the important role of endothelial cell CD40 in transplant rejection although additional downregulation of CD40 expression in other cells of the vessel wall, for example smooth muscle cells or fibroblasts, cannot be completely ruled out.
Furthermore, given the variety of STAT-1-dependent genes, the reduction in small bowel rejection and improvement in mucosal microcirculation achieved by the STAT-1 dODN in this study cannot be explained solely by downregulating CD40 expression in the graft endothelial cells, but may stem from a more general interference with IFN-g-dependent gene expression. Thus, adhesion molecules such as ICAM-1 or VCAM-1 require STAT-1 for full activation and expression, 28, 29 and these may have been targeted by the STAT-1 dODN in the graft endothelial cells as well. 
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An alternative explanation for the protective effect of the STAT-1 dODN treatment instead of preventing acute rejection is that it affects ischemia/reperfusion injury, another determinant of graft damage influencing graft survival. For our experimental model, however, we have chosen an ischemia time of 2 h that in conjunction with the time required for implantation of the graft can be regarded, on the one hand, to be sufficient for an adequate uptake of the dODN by the target cells and on the other to be too short to cause major ischemia/reperfusion injury. 30 Moreover, when comparing the various microcirculatory parameters between syngeneic and allogeneic grafts subjected to a comparatively short ischemia time, we were unable to detect any differences on postoperative day 1 or 2, indicative of a distinct ischemia/reperfusion injury in the rat small bowel transplantation model. 5 The period of ischemia following explantation before implantation is the ideal time to target gene expression in the graft endothelium since nucleic acid-based drugs such as the STAT-1 dODN can be introduced locally at a sufficiently high concentration without being washed away by the bloodstream. Systemic effects are largely minimized owing to the effective wash out of the oligonucleotides before releasing of the anastomosis clamps as described in the Materials and methods section. Even though a minor spillover into the circulation of the recipient cannot be ruled out with certainty -the detection methods available to date for such small DNA molecules are not sensitive enough -this is unlikely to account for the observed therapeutic effects owing to rapid dilution of the oligonucleotides below the level of biological efficacy and effective clearance from the circulation. Administration of this new class of nucleic acid-based drugs further offers the advantage that they do not require a transfection reagent and block their target transcription factor immediately upon uptake by the target cell.
In conclusion, the aforementioned findings demonstrate that decoy ODN neutralization of the transcription factor STAT-1 in the graft vasculature at the time of transplantation affords a pronounced protective effect even in the absence of an immunosuppressant. As this class of nucleic acid-based drugs has already been 
successfully tested in man, the described approach may provide a valuable adjunct therapy for transplant patients, especially when receiving a difficult transplant such as the small bowel.
Materials and methods
Animals
All experiments were carried out according to the guidelines for the use of laboratory animals in Germany and approved by the local authorities. Heterotopic small bowel transplantation was performed in male rats in the allogeneic Brown Norway (RT1n) to Lewis (RT1 l) strain combination without immunosuppressant therapy. The animals (body weight 250-300 g) were purchased from Charles River (Sulzfeld, Germany) and had unrestricted access to water and food. They were kept in a 12-h day and night cycle, and fed standard laboratory chow.
Decoy ODN technique
Double-stranded ODNs were prepared from complementary single-stranded phosphorothioate-bonded ODNs obtained from Eurogentec (Kö ln, Germany) by melting at 951C for 5 min, followed by a cooldown phase of 3-4 h at ambient temperature. The efficiency of the hybridization reaction was verified with 2.5% agarose gel electrophoresis and usually found to exceed 95%. The sequences of the single-stranded ODNs were as follows 
Transfection of CD40 antisense ODNs
As the uptake of naked, single-stranded DNA is rather poor when compared to double-stranded DNA, we used the amphiphilic liposome-based Smarticles technique to effectively transfect the graft. CD40 antisense and scrambled control ODN were prepared and administered after encapsulation into liposomes as described previously. 24 For application of CD40 antisense and scrambled control, ODNs were encapsulated in amphoteric liposomes. In brief, 14 mmol (1,2-dioleoyloxypropyl)-N,N,Ntrimethylammonium salt, 42 mmol cholesterylhemisuccinate and 85 mmol 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine were dissolved in chloroform in a 10 ml round bottom flask and evaporated to dryness under vacuum. One ml of buffer containing 10 mM sodium acetate, 150 mM sodium chloride and 1 mg/ml of the ODN was adjusted to pH 4.5 and used for hydration. The initial suspension was sonicated for 5 min and frozen (À701C). After thawing, liposomes were extruded 15 times through polycarbonate filters having a pore diameter of 400 nm. Liposomes were adjusted to pH 7.5 using 1 M HEPES buffer and stored at 41C. The sequences of the antisense and scrambled control ODN were as follows (underlined letters denote phosphorothioate-bonded nucleotides):
Experimental design Endpoint. In previous experiments in the same model without immunosuppression mucosal perfusion in the allografts is not different 2 days post-transplantation when compared to syngeneic controls but starts to increasingly decline from day 3 onwards until complete cessation of mucosal perfusion on day 7 after transplantation. 5 Therefore, nonperfusion was accepted as end point in transplant rejection, and all transplants were analyzed by intravital microscopy at this point in time followed by sacrifice of the animals and subsequent histological evaluation.
Ischemia time. A period of 2 h was chosen because (i) previous in vitro experiments have shown that this time is sufficient to ensure a near maximum uptake of the oligonucleotides by the endothelial cells and (ii) ischemia/reperfusion injury can be largely disregarded after this period. 30 Procedure. After explantation of the small bowel the grafts were randomly assigned to the following groups:
Control group (Control). The donor graft vessels were manually infused with 2 ml Ringer solution and the grafts stored for 2 h at 41C until implantation (n ¼ 8). During implantation just before completion of the anastomosis and restoration of blood flow, graft vessels were thoroughly rinsed with Ringer solution (total 
STAT-1 dODN (STAT).
The donor blood vessels were manually infused with 2 ml Ringer solution containing 20 mM STAT-1 dODN (n ¼ 8). After 2 h of cold ischemia, the grafts were implanted and the nucleic acid solution was flushed out as described above for the control group.
Mutant control ODN (STAT mut). The donor blood vessels were manually infused with 2 ml Ringer solution containing 20 mM mutant control ODN (n ¼ 8). After 2 h of cold ischemia, the grafts were implanted and the nucleic acid solution was flushed out as described above for the control group.
CD40 antisense ODN (AS) or scrambled control ODN (SCR). To verify a role for CD40 in rejection, two further groups of animals (n ¼ 3) received donor small bowel transplants pretreated with the CD40 antisense ODN (AS) or the corresponding scrambled control ODN (SCR). To this end, the donor blood vessels were manually infused with 2 ml Ringer solution containing the liposomal CD40 antisense ODN or scrambled control ODN formulation (2.7 mg DNA in a total volume of 100 ml). After 2 h of cold ischemia, the grafts were implanted and the liposomal formulation was flushed out as described above for the control group.
Microsurgical technique
Heterotopic transplantation of the entire small bowel was performed under ether anesthesia as described previously. 31 Briefly, after complete excision of the small bowel donor vessels were infused with 2 ml Ringer solution containing the corresponding nucleic acids or vehicle. Thereafter, the graft was removed with an aortic conduit from the animal and stored in UW solution for 2 h at 41C until revascularization. Revascularization was completed by end-to-side anastomosis of the aortic conduit and the portal vein to the abdominal aorta and the inferior vena cava, respectively.
Intravital microscopy
Intravital microscopic analysis of the transplanted small bowel was performed as described in detail elsewhere. 5 
Microcirculatory blood flow analysis
To characterize overall mucosal perfusion, a perfusion index (PI) was calculated by using the equation
where V p represents the number of perfused villi, V ip the number of all irregularly perfused villi and V t the total number of villi observed. 32 To characterize overall mucosal perfusion damage, a stasis index (SI) was calculated as follows:
where V np represents the number of nonperfused villi and V t the total number of all villi observed.
Further analysis of microcirculatory parameters in the mucosa and muscle layers included the assessment of FCD (length of perfused capillaries per villus area (1/cm) at a magnification of Â 476) and RBCV (in mm/s at a magnification of 933 Â ). 33 Analyses of FCD and RBCV (line-to-shift analysis) 34 were performed by using the CAPIMAGE software (Zeintl, Heidelberg, Germany). By using the fluorescent marker Rhodamine 6G adherent leukocytes were identified in each vessel segment (100 mm) and counted as cells that did not move or detach from the endothelium within an observation period of 30 s. Their number was calculated from the diameter and length of the blood vessel, assuming a cylindrical geometry and expressed as number of cells per mm 2 .
30
Histology Full-thickness small bowel biopsy specimens obtained at the end of each experiment were immediately fixed in 4% formaldehyde, processed for standard light microscopy and stained with hematoxylin-eosin. Rejection was graded histologically using a scheme for grading of small intestine allograft rejection by an experienced pathologist in a blinded fashion. 35 
Immunohistochemistry
Five micrometers thick paraffin sections were placed on Superfrost slides. They were deparaffinized with xylene and rehydrated in ethanol. After antigen retrieval by steaming in citrate buffer, slides were incubated for 1 h at ambient temperature in a humidity chamber with the primary antibody (mouse anti-rat CD3; Serotec, Duesseldorf, Germany), washed in Tris-buffered saline (TBS), incubated with a secondary antimouse biotinylated antibody (DCS Innovative Diagnostic Systems, Hamburg, Germany) at ambient temperature for 20 min, washed, and incubated with streptavidin-horseraddish perioxidase (HRP) complex. After development with 3,3-diaminobenzidine substrate (Roche Diagnostics, Penzberg, Germany), sections were counterstained with haematoxylin and mounted in Aquamount (BDH Laboratory Supplies, Poole, UK). Primary antibodies were omitted in controls. Negative controls were included in every series as well as positive reference sections for quality control purposes. Quantitative determination of CD3-expressing cells was performed manually by counting the positively stained cells in five high-power fields ( Â 400) per slide in a blinded fashion.
Apoptosis assay
To detect apoptotic cell death, tissue sections were stained using the in situ cell death detection kit POD (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. After mounting the coverslips with aquamount, sections were examined under the light microscope. Apoptotic bodies were counted manually in the whole graft in 10 randomly chosen high-power fields ( Â 400) in a blinded fashion and expressed as number of cells per high-power field.
Western blot analysis of CD40 protein
As immunohistochemical detection of CD40 abundance in the small bowel grafts proved to be unsatisfactory and inconclusive, this was analyzed instead in whole-tissue homogenates by Western blot analysis according to standard protocols. 22 A polyclonal rabbit anti-rat CD40 antibody (Biovision, San Diego, USA) was used as the primary antibody at 1:500 dilution. A HRP-conjugated goat anti-rabbit IgG antibody (Sigma-Aldrich, 1:3000 dilution) was used as the secondary antibody. Equal loading and transfer of protein was verified by reprobing the STAT-1 decoy oligonucleotide and transplant rejection T Stojanovic et al membrane with a monoclonal anti-b-actin antibody (Sigma-Aldrich, 1:3000 dilution). The intensity of the immunoreactive bands was quantified by densitometry. 22 
Statistical analysis
The SPSS v10.0. computer program (SPSS Inc., Chicago, IL, USA) was used for all calculations and statistical evaluations. Results in diagrams were expressed as means 7 standard error of the mean (s.e.m.) in each group. The groups were compared using the nonparametric Mann-Whitney U-test with a P-value o0.05 considered statistically significant.
